{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T13:12:18Z","timestamp":1774444338093,"version":"3.50.1"},"reference-count":54,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872932"],"award-info":[{"award-number":["81872932"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-5-011"],"award-info":[{"award-number":["2021-I2M-5-011"]}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","award":["SZSM202301035"],"award-info":[{"award-number":["SZSM202301035"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Metabolic disorder-associated fatty liver disease (MASLD) is closely related to obesity and type 2 diabetes. Its pathogenesis involves many factors, including mitochondrial dysfunction, endoplasmic reticulum stress and intestinal flora disorders. Notoginsenoside R1 (NGR1) is a key bioactive component of Panax notoginseng. The purpose of this study was to investigate the therapeutic effect of notoginsenoside R1 (NGR1) on metabolic disorder-associated steatohepatitis (MASH) and its potential mechanism. Methods: Mice were fed a choline-deficient, L-amino acid-defined high-fat diet (CDAHFD) for 6 weeks and received NGR1 (50\/100 mg\/kg\/day) in the last 3 weeks. The role of NGR1 was evaluated by developing metabolomics, proteomics and functional analysis. In addition, the effects of NGR1 on lipid droplet content, mitochondrial function and fatty acid oxidation in hepatocytes were also verified. Results: NGR1 improved MASH progression in CDAHFD-fed mice, significantly reduced liver triglyceride content from 31.2 \u00b1 5.1 mmol\/g to 20.5 \u00b1 4.8 mg\/g (p &lt; 0.001), free fatty acid from 0.12 \u00b1 0.03 mmol\/g prot to 0.06 \u00b1 0.028 mg\/g (p &lt; 0.001), TNF-\u03b1 (p &lt; 0.01), IL-1\u03b2 (p &lt; 0.001), \u03b1-SMA (p &lt; 0.05) and Collagen1A1 levels (p &lt; 0.01), as well as serum ALT and AST concentrations (p &lt; 0.001), and alleviated hepatomegaly and lipid droplet accumulation. Metabolomics and proteomics analysis showed that NGR1 normalized liver metabolism in MASH mice and upregulated mitochondrial OXPHOS components, including NADH: ubiquinone oxidoreductase core subunit S2 (NDUFS2), and effectively reversed CDAHFD-induced mitochondrial dysfunction. Mitochondrial membrane potential and ATP production were restored. Conclusions: This study confirmed that NGR1 has significant therapeutic potential for MASH and improves mitochondrial function by upregulating NDUFS2. This study provides new insights for the future clinical treatment of MASH.<\/jats:p>","DOI":"10.3390\/ph19040524","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:07:13Z","timestamp":1774433233000},"page":"524","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["NGR1 Ameliorates Hepatocyte Steatosis and Mitochondrial Dysfunction Associated with the Restoration of NDUFS2"],"prefix":"10.3390","volume":"19","author":[{"given":"Min","family":"Liu","sequence":"first","affiliation":[{"name":"Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsheng","family":"Liu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5096-4025","authenticated-orcid":false,"given":"Jiye","family":"Aa","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangji","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China"},{"name":"Research Unit of PK-PD Based Bioactive Components and Pharmacodynamic Target Discovery of Natural Medicine, Chinese Academy of Medical Sciences, Beijing 100700, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Xie","sequence":"additional","affiliation":[{"name":"Key Laboratory of Drug Metabolism and Pharmacokinetics, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1146\/annurev-pathol-012615-044224","article-title":"Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum","volume":"11","author":"Hardy","year":"2016","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/hep.21103","article-title":"Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C","volume":"43","author":"Sanyal","year":"2006","journal-title":"Hepatology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1002\/hep.26986","article-title":"Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S","volume":"59","author":"Wong","year":"2014","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/liv.13302","article-title":"Therapies in non-alcoholic steatohepatitis (NASH)","volume":"37","author":"Oseini","year":"2017","journal-title":"Liver Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DMSO.S146339","article-title":"Obesity and nonalcoholic fatty liver disease: Current perspectives","volume":"11","author":"Sarwar","year":"2018","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jare.2024.03.009","article-title":"The role of extracellular vesicles in non-alcoholic steatohepatitis: Emerging mechanisms, potential therapeutics and biomarkers","volume":"69","author":"Wang","year":"2025","journal-title":"J. Adv. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1111\/liv.15930","article-title":"The first MASH drug therapy on the horizon: Current perspectives of resmetirom","volume":"44","author":"Petta","year":"2024","journal-title":"Liver Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e186425","DOI":"10.1172\/JCI186425","article-title":"Therapeutic horizons in metabolic dysfunction\u2013associated steatohepatitis","volume":"135","author":"Newsome","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1007\/s10495-016-1295-5","article-title":"Mitochondrial dynamics during cell cycling","volume":"21","author":"Horbay","year":"2016","journal-title":"Apoptosis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.tem.2016.11.006","article-title":"Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies","volume":"28","author":"Sunny","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.mito.2020.12.010","article-title":"Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD)","volume":"57","author":"Ajaz","year":"2021","journal-title":"Mitochondrion"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.bbrc.2020.03.180","article-title":"Effect of methionine\/choline-deficient diet and high-fat diet-induced steatohepatitis on mitochondrial homeostasis in mice","volume":"527","author":"Arao","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/hep.32324","article-title":"Compromised hepatic mitochondrial fatty acid oxidation and reduced markers of mitochondrial turnover in human NAFLD","volume":"76","author":"Moore","year":"2022","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/hep.31789","article-title":"Clinical Implications of HBV PreS\/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development","volume":"74","author":"Liang","year":"2021","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell Mol. Life Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.bbamcr.2016.01.023","article-title":"Carnitine transport and fatty acid oxidation","volume":"1863","author":"Longo","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1517\/13543784.2014.892582","article-title":"Saponins of Panax notoginseng: Chemistry, cellular targets and therapeutic opportunities in cardiovascular diseases","volume":"23","author":"Liu","year":"2014","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1211\/jpp.58.8.0001","article-title":"Pharmacological activity of sanchi ginseng (Panax notoginseng)","volume":"58","author":"Ng","year":"2006","journal-title":"J. Pharm. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chen, P., Gao, Z., Guo, M., Pan, D., Zhang, H., Du, J., and Shi, D. (2024). Efficacy and safety of Panax notoginseng saponin injection in the treatment of acute myocardial infarction: A systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1353662"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2147\/DDDT.S240511","article-title":"Focus on Notoginsenoside R1 in Metabolism and Prevention Against Human Diseases","volume":"14","author":"Liu","year":"2020","journal-title":"Drug Des. Devel Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.1080\/21655979.2022.2037366","article-title":"Notoginsenoside R1 relieves the myocardial infarction via activating the JAK2\/STAT3 signaling pathway in vivo and in vitro","volume":"13","author":"Xu","year":"2022","journal-title":"Bioengineered"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/s41401-023-01057-y","article-title":"Notoginsenoside R1 protects against myocardial ischemia\/reperfusion injury in mice via suppressing TAK1-JNK\/p38 signaling","volume":"44","author":"Zeng","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lei, W., Yan, Y., Ma, Y., Jiang, M., Zhang, B., Zhang, H., and Li, Y. (2022). Notoginsenoside R1 Regulates Ischemic Myocardial Lipid Metabolism by Activating the AKT\/mTOR Signaling Pathway. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.905092"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Tian, X., Chen, X., Jiang, Q., Sun, Q., Liu, T., Hong, Y., Zhang, Y., Jiang, Y., Shao, M., and Yang, R. (2022). Notoginsenoside R1 Ameliorates Cardiac Lipotoxicity Through AMPK Signaling Pathway. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.864326"},{"key":"ref_29","first-page":"65","article-title":"Inhibiting effects and mechanisms of notoginsenoside R1 on liver lipiddeposition in ApoE knocked out mice","volume":"52","author":"Minqi","year":"2018","journal-title":"Shanghai J. Tradit. Chin. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1142\/S0192415X22500197","article-title":"Notoginsenoside R1, An Active Compound from Panax notoginseng, Inhibits Hepatic Stellate Cell Activation and Liver Fibrosis via MAPK Signaling Pathway","volume":"50","author":"Gong","year":"2022","journal-title":"Am. J. Chin. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1080\/21691401.2019.1610414","article-title":"Notoginsenoside R1 alleviates lipopolysaccharide-triggered PC-12 inflammatory damage via elevating microRNA-132","volume":"47","author":"Sun","year":"2019","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2018.04.006","article-title":"CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis","volume":"69","author":"Zhao","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcmgh.2023.10.002","article-title":"GPAT1 Deficiency in Mice Modulates NASH Progression in a Model-Dependent Manner","volume":"17","author":"Smith","year":"2024","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.2147\/DMSO.S360931","article-title":"Palmitate Induces Mitochondrial Energy Metabolism Disorder and Cellular Damage via the PPAR Signaling Pathway in Diabetic Cardiomyopathy","volume":"15","author":"Zhang","year":"2022","journal-title":"Diabetes Metab. Syndr. Obes."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/ncomms1755","article-title":"FAD-dependent lysine-specific demethylase-1 regulates cellular energy expenditure","volume":"3","author":"Hino","year":"2012","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"103014","DOI":"10.1016\/j.ebiom.2020.103014","article-title":"Hypothermic oxygenated perfusion protects from mitochondrial injury before liver transplantation","volume":"60","author":"Schlegel","year":"2020","journal-title":"eBioMedicine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/sj.emboj.7601633","article-title":"Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1\/PGC-1alpha","volume":"26","author":"Rodgers","year":"2007","journal-title":"Embo J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8248","DOI":"10.1039\/D0FO01219J","article-title":"Exogenous natural EPA-enriched phosphatidylcholine and phosphatidylethanolamine ameliorate lipid accumulation and insulin resistance via activation of PPAR\u03b1\/\u03b3 in mice","volume":"11","author":"Tian","year":"2020","journal-title":"Food Funct."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.bbadis.2018.06.023","article-title":"Animal models of NAFLD from a hepatologist\u2019s point of view","volume":"1865","author":"Jahn","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/iep.12008","article-title":"An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis","volume":"94","author":"Matsumoto","year":"2013","journal-title":"Int. J. Exp. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/path.4829","article-title":"Animal models of non-alcoholic fatty liver disease: Current perspectives and recent advances","volume":"241","author":"Lau","year":"2017","journal-title":"J. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2337\/db06-0097","article-title":"A choline-deficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high-fat diet","volume":"55","author":"Raubenheimer","year":"2006","journal-title":"Diabetes"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"G1281","DOI":"10.1152\/ajpgi.00074.2008","article-title":"Gene expression in human NAFLD","volume":"294","author":"Greco","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.2337\/db14-0369","article-title":"Free fatty acid uptake in humans with CD36 deficiency","volume":"63","author":"Hames","year":"2014","journal-title":"Diabetes"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41594-022-00884-7","article-title":"Structural basis of the acyl-transfer mechanism of human GPAT1","volume":"30","author":"Johnson","year":"2023","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3945\/an.111.000737","article-title":"Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state","volume":"2","author":"Adams","year":"2011","journal-title":"Adv. Nutr."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00726-014-1894-9","article-title":"Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease","volume":"47","author":"Lake","year":"2015","journal-title":"Amino Acids"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/s41580-019-0123-5","article-title":"Metabolic regulation of cell growth and proliferation","volume":"20","author":"Zhu","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5921","DOI":"10.1210\/jc.2003-030885","article-title":"Decreased fatty acid beta-oxidation in riboflavin-responsive, multiple acylcoenzyme A dehydrogenase-deficient patients is associated with an increase in uncoupling protein-3","volume":"88","author":"Russell","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Schirrmacher, V. (2020). Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism. Biomedicines, 8.","DOI":"10.3390\/biomedicines8110526"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"11278","DOI":"10.1111\/jcmm.17054","article-title":"Notoginsenoside R1 attenuates oxidative stress-induced osteoblast dysfunction through JNK signalling pathway","volume":"25","author":"Li","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1002\/ptr.7450","article-title":"Notoginsenoside R1 ameliorates mitochondrial dysfunction to circumvent neuronal energy failure in acute phase of focal cerebral ischemia","volume":"36","author":"Liu","year":"2022","journal-title":"Phytother. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1189\/jlb.71.3.388","article-title":"The role of PPARs in inflammation and immunity","volume":"71","author":"Clark","year":"2002","journal-title":"J. Leukoc. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.mito.2021.03.003","article-title":"Complex I protein NDUFS2 is vital for growth, ROS generation, membrane integrity, apoptosis, and mitochondrial energetics","volume":"58","author":"Bandara","year":"2021","journal-title":"Mitochondrion"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/4\/524\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:24:52Z","timestamp":1774434292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/4\/524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":54,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["ph19040524"],"URL":"https:\/\/doi.org\/10.3390\/ph19040524","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]}}}